217 related articles for article (PubMed ID: 24084771)
21. Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.
Kim KP; Ryu MH; Yoo C; Ryoo BY; Choi DR; Chang HM; Lee JL; Beck MY; Kim TW; Kang YK
Cancer Chemother Pharmacol; 2011 Aug; 68(2):285-91. PubMed ID: 20957481
[TBL] [Abstract][Full Text] [Related]
22. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Heinrich MC; Maki RG; Corless CL; Antonescu CR; Harlow A; Griffith D; Town A; McKinley A; Ou WB; Fletcher JA; Fletcher CD; Huang X; Cohen DP; Baum CM; Demetri GD
J Clin Oncol; 2008 Nov; 26(33):5352-9. PubMed ID: 18955458
[TBL] [Abstract][Full Text] [Related]
23. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
Nishida T; Omori T; Ueshima S
Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
[TBL] [Abstract][Full Text] [Related]
24. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
George S; Reichardt P; Lechner T; Li S; Cohen DP; Demetri GD
Ann Oncol; 2012 Dec; 23(12):3180-3187. PubMed ID: 22858558
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.
Benjamin RS; Schöffski P; Hartmann JT; Van Oosterom A; Bui BN; Duyster J; Schuetze S; Blay JY; Reichardt P; Rosen LS; Skubitz K; McCoy S; Sun YN; Stepan DE; Baker L
Cancer Chemother Pharmacol; 2011 Jul; 68(1):69-77. PubMed ID: 20838998
[TBL] [Abstract][Full Text] [Related]
26. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
27. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK
Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib.
Paz-Ares L; García del Muro X; Grande E; González P; Brosa M; Díaz S
Clin Transl Oncol; 2008 Dec; 10(12):831-9. PubMed ID: 19068454
[TBL] [Abstract][Full Text] [Related]
29. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D;
Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858
[TBL] [Abstract][Full Text] [Related]
30. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202).
Nishida T; Shirao K; Sawaki A; Koseki M; Okamura T; Ohtsu A; Sugiyama T; Miyakawa K; Hirota S
Int J Clin Oncol; 2008 Jun; 13(3):244-51. PubMed ID: 18553235
[TBL] [Abstract][Full Text] [Related]
32. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
[TBL] [Abstract][Full Text] [Related]
33. Activity of nilotinib (AMN-107) alone in advanced gastrointestinal stromal tumors progressing on imatinib and sunitinib. Case report.
Sevinc A
Chemotherapy; 2009; 55(2):132-6. PubMed ID: 19188713
[TBL] [Abstract][Full Text] [Related]
34. Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib.
Ruka W; Rutkowski P; Szawłowski A; Nowecki Z; Debiec-Rychter M; Grzesiakowska U; Dziewirski W; Siedlecki JA; Michej W
Eur J Surg Oncol; 2009 Jan; 35(1):87-91. PubMed ID: 18289826
[TBL] [Abstract][Full Text] [Related]
35. Novel approaches to imatinib- and sunitinib-resistant GIST.
Reichardt P
Curr Oncol Rep; 2008 Jul; 10(4):344-9. PubMed ID: 18778561
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.
Son MK; Ryu MH; Park JO; Im SA; Kim TY; Lee SJ; Ryoo BY; Park SR; Kang YK
Cancer Res Treat; 2017 Apr; 49(2):350-357. PubMed ID: 27456941
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.
Doi T; Kurokawa Y; Sawaki A; Komatsu Y; Ozaka M; Takahashi T; Naito Y; Ohkubo S; Nishida T
Eur J Cancer; 2019 Nov; 121():29-39. PubMed ID: 31536852
[TBL] [Abstract][Full Text] [Related]
38. Nilotinib in advanced gastrointestinal stromal tumors after imatinib and sunitinib therapy.
Dizdar O; Yalcin S
Hepatogastroenterology; 2011; 58(112):2012-4. PubMed ID: 22024073
[TBL] [Abstract][Full Text] [Related]
39. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
[TBL] [Abstract][Full Text] [Related]
40. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]